
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. exhibits a promising trajectory in its clinical-stage development of antibody therapeutics, bolstered by favorable biomarker and safety data that support the continued investment in its lead candidate, PMN310. The company’s innovative approach highlights PMN267's dual selectivity profile, which is anticipated to enhance its potential in treating multiple neurodegenerative diseases, thus broadening its development horizon. Additionally, the absence of adverse reactions such as ARIA in PMN310 positions it favorably against competitive products, suggesting a superior safety profile that may attract further investor confidence and drive future growth.
Bears say
ProMIS Neurosciences Inc. reported a substantial net loss of $11.6 million for Q3 2025, equating to a loss of $0.24 per share, underscoring ongoing financial challenges as the company remains unprofitable. Significant risks linger in potential future partnerships and a slower-than-anticipated market uptake, primarily due to heightened competition in the biotechnology sector. Moreover, the company's reliance on a novel therapeutic approach targeting toxic Aβ oligomers faces hurdles, especially following the lack of efficacy observed in clinical trials for similar therapies, raising concerns about the effectiveness and commercial viability of their products.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares